Education case: A case-based approach to overlap autoimmune liver disease in patient with ulcerative colitis
Gastroenterology and Hepatology from Bed to Bench,
Simultaneous occurrence of immune-based gastrointestinal diseases and autoimmune hepatitis although is not common but is of clinical importance. Some clinical and laboratory findings such as severe pruritus and an elevation in alkaline phosphatase raise suspicion of a biliary disease which overlaps autoimmune hepatitis. A strong clinical suspicion of overlap syndrome in a patient with autoimmune hepatitis prompts more diagnostic evaluations like MRCP, liver biopsy and secondary laboratory tests. Patients who fall into the category of overlap syndrome would be proceeded with timely monitoring of known complications including colorectal carcinomas, cholangiocarcinomas and gallbladder cancers. So, it is highly recommended to search for all simultaneous immune-based involvements prior to labelling a patient as having pure autoimmune hepatitis.
In this study, attempts have been made to express all challenges about a case with overlap syndrome referred to gastroenterology ward of Taleghani hospital and review the latest articles and related guidelines about the diagnosis, treatment, complications, and surveillance of the mentioned patient with autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), and inflammatory bowel disease (IBD).
Keywords: Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Inflammatory Bowel Disease, Ulcerative Colitis, overlap syndrome.
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Inflammatory Bowel Disease, Ulcerative Colitis, overlap syndrome.
How to Cite
2. Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests. Gut 2018; 67:6.
3. Lala V, Goyal A, Bansal P, et al. Liver Function Tests. [Updated 2020 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-.
4. Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 2019.
5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63:971.
6. Gleeson D, Heneghan MA, British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60:1611.
7. Canh HN, Harada K, Ouchi H, Sato Y, Tsuneyama K, Kage M, et al. Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients. Journal of clinical pathology. 2017; 70(11):961-969.
8. Björnsson E, Talwalkar J, Treeprasertsuk S, et al. Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis. Clin Gastroenterol Hepatol 2011; 9:57.
9. Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplied International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009; 50:538.
10. Pape S, Gevers TJG, Belias M, et al. Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2019; 17:2068.
11. Hübener S, Oo YH, Than NN, et al. Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance. Clin Gastroenterol Hepatol 2016; 14:445.
12. Benedetta Terziroli Beretta-Piccoli, Giorgina Mieli-Vergani, Diego VerganiWorld J. Autoimmune hepatitis: standard treatment and systematic review of alternative treatments. Gastroenterol 2017 September 7; 23(33): 6030-6048.
13. Yooyun Chung, Mussarat N Rahim, Jonathon J Graham, Yoh Zen & Michael A Heneghan (2021) An update on the pharmacological management of autoimmune hepatitis, Expert Opinion on Pharmacotherapy, DOI: 10.1080/14656566.2021.1895747
14. Cropley A, Weltman M. The use of immunosuppression in autoimmune hepatitis: A current literature review. Clin Mol Hepatol 2017; 23(1): 22-26.
15. Paiseler M, Liebscher T, Sebode M, Zenouzi R, Hartl J, Ehlken H, et al. Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, Volume 16, Issue 2, February 2018, Pages 155-156.
16. Dhaliwal, Harpreet K MB, ChB, MRCP1; Hoeroldt, Barbara S MB, PhD, FRCP2; Dube, Asha K BSc (Hons), MBChB, FRCPath3; McFarlane, Elaine SRN, MSc1; Underwood, James C E MD, FRCPath4; Karajeh, Mohammed A MB, FRCP1; Gleeson, Dermot MD, BSc, FRCP1 Long-Term Prognostic Significance of Persisting Histological Activity Despite Biochemical Remission in Autoimmune Hepatitis, American Journal of Gastroenterology: July 2015 - Volume 110 - Issue 7 - p 993-999 doi: 10.1038/ajg.2015.139.
17. Hoeroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140:1980.
18. Gossard AA, Lindor KD. Autoimmune hepatitis: a review. J Gastroenterol 2012; 47:498.
19. Ngu JH, Gearry RB, Frampton CM, Stedman CA. Predictors of poor outcome in patients with autoimmune hepatitis: a population-based study. Hepatology 2013; 57:2399.
20. Li, Y., Yan, L., Wang, R. et al. Serum Immunoglobulin G Levels Predict Biochemical and Histological Remission of Autoimmune Hepatitis Type 1: A Single-Center Experience and Literature Review. Clinic Rev Allerg Immunol (2021). https://doi.org/10.1007/s12016-021-08833-w
21. Johannes Hartl, Hanno Ehlken, Marcial Sebode, Moritz Peiseler, Till Krech, Roman Zenouzi, Johann von Felden, Christina Weiler-Normann, Christoph Schramm, Ansgar W Lohse. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. Journal of hepatology 68 (4), 754-763, 2018.
22. Mussarat N. Rahim, Rodrigo Liberal, Rosa Miquel, Nigel D. Heaton, Michael A. Heneghan. Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation? Liver Transplantation; 25 (6): 946-959.
23. Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59:1144.
24. Jeremy S. Nayagam, Rosa Miquel, Deepak Joshi. Overlap Syndrome with Autoimmune Hepatitis and Primary Sclerosing Cholangitis. EMJ Hepatol. 2019;7:95-104.
25. Lewin M et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: A prospective magnetic resonance imaging and histological study. Hepatology. 2009;50(2):528-37.
26. To y, Silveira M. Overlap syndrome of autoimmune hepatitis and primary biliary sclerosis. Clinics in Liver Disease. 2018; 22(3):603-611.
27. Vierling J.M. Autoimmune hepatitis and overlap syndromes: diagnosis and management. Clin Gastroenterol Hepatol. 2015; 13: 2088-2108.
28. Lindor KD, Kowdley KV, Harrison ME, American College of Gastroenterology. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol 2015; 110:646.
29. Isayama H, Tazuma S, Kokudo N, Tanaka A, Tsuyuguchi T, Nakazawa T, et al. Clinical guidelines for primary sclerosing cholangitis 2017. J Gastroenterol; 2018; 53: 1006-1034.
30. Einar S. Björnsson & Evangelos Kalaitzakis (2020): Recent advances in the treatment of primary sclerosing cholangitis, Expert Review of Gastroenterology & Hepatology, DOI: 10.1080/17474124.2021.1860751.
31. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51:660.
32. Bowlus CL, Lim JK, Lindor KD. AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. Clin Gastroenterol Hepatol 2019; 17:2416.
33. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68:723.
34. Fevery J, Henckaerts L, Van Oirbeek R, et al. Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study. Liver Int 2012; 32:214.
35. Pai RK, Jairath V, Casteele NV, Rieder F, Parker CE, Lauwers GY. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointestinal endoscopy. 2018; 88(6):887-898.
36. Ozaki R, Kobayashi T, Okabayashi S, Nakano M, Morinaga S, Hara A, et al. Histological risk factors to predict clinical relapse in ulcerative colitis with endoscopically normal mucosa. Journal of Crohn’s and Colitis. 2018; 12 (11):1288-1294.
37. Chrisinger JA, Dassopoulos T, Yan Y, Nalbantoglu. Primary sclerosing cholangitis associated colitis: Characterization of clinical, histologic features, and their associations with liver transplantation. World J Gastroenterol 2020 July 28; 26(28): 4126-4139.
38. Ricciuto A, KamathM, Griffiths A. The IBD and PSC phenotypes of PSC-IBD. Current gastroenterology reports 20 (4), 1-13, 2018.
39. Fraga, Montserrat; Fournier, Nicolas; Safroneeva, Ekaterina; Pittet, Valérie; Godat, Sébastien; Straumann, Alex ; Nydegger, Andreas ; Vavricka, Stephan R ; Moradpour, Darius ; Schoepfer, Alain M. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. European Journal of Gastroenterology & Hepatology. 2017; 29 (1): 91-97.
40. Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz S. Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut and liver 12 (1), 17, 2018.
41. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. American Journal of Gastroenter ology 114 (3), 384-413, 2018.
42. Ko WC, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology 156 (3), 748-764, 2019.
43. Karnsund S, Lo B, Bendtsen F, Holm J, Burisch J. Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. World J Gastroenterol 2020 September 21; 26(35): 5362-5374.
44. Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol 2015; 11: 98-109 [PMID: 25385412 DOI: 10.1038/nrrheum.2014.188].
45. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2017; 112: 241-258 [PMID: 28071656 DOI: 10.1038/ajg.2016.537].
46. Lo B, Holm JP, Vester-Andersen MK, Bendtsen F, Vind I, Burisch J. Incidence, Risk Factors and Evaluation of Osteoporosis in Patients With Inflammatory Bowel Disease: A Danish Population-Based Inception Cohort With 10 Years of Follow-Up. J Crohns Colitis 2020; 14: 904-914 [PMID: 32016388 DOI: 10.1093/ecco-jcc/jjaa019].
47. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:309.
48. Kim DK, Hunter P, Advisory Committee on Immunization Practices. Recommended Adult Immunization Schedule, United States, 2019. Ann Intern Med 2019; 170:182.
49. American Society for Gastrointestinal Endoscopy Standards of Practice Committee, Shergill AK, Lightdale JR, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81:1101. 4.
50. Baars JE, Kuipers EJ, van Haastert M, et al. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol. 2012; 47:1308.
51. Annese V, Beaugerie L, Egan L, et al. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015; 9:945.
52. Ricci C, Scaldaferri F, Colombo F, Armuzzi A, Lopetuso LR, Leone S, et al. Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: a multidisciplinary management experience. European Review for Medical and Pharmacological Sciences. 2020; 24: 564-570.
53. Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA. 2017; 318:1679.
54. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015; 13:847.
- Abstract Viewed: 0 times